Neomorph announced the closing of a $100 million Series B financing.
- Amount
- $100M
- Stage
- Series B
- Announced
- 13 April 2026
- Lead
- Deerfield Management
- Other investors
- Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital of Dana-Farber Cancer Institute
- Use of funds
- Primarily supports the ongoing NEO-811 Phase 1/2 trial and advancement of broader molecular glue degrader pipeline.
- Checked
- Amount and date checked against the press source